Synthetic tuftsin analog neuropeptide (anxiolytic research; approved in Russia)
N-acetyl Selank
A tuftsin-derived peptide studied for anxiolytic and nootropic effects; Western human evidence remains limited.
- Evidence:
- Limited human evidence
- Status:
- Approved outside the U.S. (context-specific)
- Reviewed:
- 2026-08-03
Also known as: TP-7, N-acetyl Selank
What is N-acetyl Selank?
A tuftsin-derived peptide studied for anxiolytic and nootropic effects; Western human evidence remains limited.
This profile is educational. It organizes publicly discussed research context for N-acetyl Selank and related naming aliases — it is not a treatment guide.
Proposed mechanism
Proposed modulation of GABAergic and serotonergic systems, enkephalin degradation, and BDNF expression.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Limited human evidence
Preclinical evidence grade: Moderate human evidence
Selank is approved in Russia as an anxiolytic (Tuftsin analog). Russian clinical studies report anxiolytic effects without sedation. Western independent trials are sparse. Intranasal delivery is commonly discussed; nasal bioavailability for many peptides is poorly characterized in rigorous human PK studies. WADA status varies by formulation.
Key uncertainties
- Replication of Russian trial results
- Cognitive enhancement magnitude
Research areas being studied
- Anxiety research
- Nootropic research
- Immune modulation
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Generally reported as well tolerated in Russian studies
- Fatigue rare
Additional risks & considerations
- Limited Western validation
- Unregulated N-acetyl versions
- Unknown drug interactions
Regulatory status
Approved outside the U.S. (context-specific)
Registered in Russia; not FDA approved.
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is N-acetyl Selank?
A tuftsin-derived peptide studied for anxiolytic and nootropic effects; Western human evidence remains limited.
How does N-acetyl Selank work (proposed mechanism)?
Proposed modulation of GABAergic and serotonergic systems, enkephalin degradation, and BDNF expression.
What is N-acetyl Selank being researched for?
N-acetyl Selank has been discussed in research contexts including: Anxiety research, Nootropic research, Immune modulation.
What does current evidence say about N-acetyl Selank?
Limited human evidence. Selank is approved in Russia as an anxiolytic (Tuftsin analog). Russian clinical studies report anxiolytic effects without sedation. Western independent trials are sparse. Intranasal delivery is commonly discussed; nasal bioavailability for many peptides is poorly characterized in rigorous human PK studies. WADA status varies by formulation.
What safety considerations are noted for N-acetyl Selank?
Reported or discussed considerations include: Generally reported as well tolerated in Russian studies; Fatigue rare; Limited Western validation; Unregulated N-acetyl versions; Unknown drug interactions. This is educational information, not medical advice.
Is N-acetyl Selank FDA approved?
Approved outside the U.S. (context-specific). Registered in Russia; not FDA approved.
References & sources
- Uchakina ON et al. (2008). Selank anxiolytic peptide clinical research in Russia — Bull Exp Biol Med. Evidence type: human.
Prefer interactive tools? Open the PepGuide library entry for N-acetyl Selank or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.